Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Exploring drug shortages in European markets: the causes, analysis, and response – Pharmaceutical Technology

Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages. Previously, shortages were dictated by production capacity and

November 25, 2024

Teva plans sale of API unit amid ‘pivot to growth’

Teva’s drug ingredients unit is apparently not making the pivot. Less than a year into its “pivot to growth” strategy, Teva has announced plans to

February 1, 2024

New screening tool assesses digital health readiness in diverse patient populations

In a new study published in JAMA Network Open, researchers at Thomas Jefferson University have developed a novel screening tool to measure digital health readiness,

September 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.